Wealthstreet Investment Advisors LLC raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,720 shares of the pharmaceutical company’s stock after buying an additional 880 shares during the period. Wealthstreet Investment Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $6,367,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in VRTX. Evolution Wealth Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $32,000. FTB Advisors Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 1,618.2% in the 1st quarter. FTB Advisors Inc. now owns 189 shares of the pharmaceutical company’s stock valued at $35,000 after acquiring an additional 178 shares during the last quarter. Pittenger & Anderson Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 64.7% in the 1st quarter. Pittenger & Anderson Inc. now owns 191 shares of the pharmaceutical company’s stock valued at $35,000 after acquiring an additional 75 shares during the last quarter. Thor Advisors LLC bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at about $37,000. Finally, Pearl River Capital LLC bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at about $44,000. 94.91% of the stock is owned by institutional investors.

VRTX has been the subject of a number of analyst reports. Credit Suisse Group initiated coverage on shares of Regeneron Pharmaceuticals in a report on Monday, May 20th. They issued a “neutral” rating and a $336.00 price target for the company. Citigroup cut Barrick Gold to a “neutral” rating in a report on Thursday, May 23rd. Evercore ISI assumed coverage on Homology Medicines in a report on Thursday, April 11th. They set an “outperform” rating and a $29.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $10.00 target price (down previously from $15.00) on shares of Nabriva Therapeutics in a report on Wednesday, May 1st. Finally, Goldman Sachs Group upgraded Lenovo Group from a “neutral” rating to a “buy” rating in a report on Thursday, May 23rd. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $205.00.

VRTX stock traded up $4.00 during trading on Tuesday, reaching $170.23. The company’s stock had a trading volume of 35,719 shares, compared to its average volume of 943,940. Vertex Pharmaceuticals Incorporated has a 1 year low of $151.80 and a 1 year high of $195.81. The company has a quick ratio of 3.66, a current ratio of 3.78 and a debt-to-equity ratio of 0.13. The firm has a market cap of $42.57 billion, a P/E ratio of 60.21, a P/E/G ratio of 2.41 and a beta of 1.43. The company has a fifty day moving average price of $176.33.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.49. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. The company had revenue of $857.00 million for the quarter, compared to the consensus estimate of $853.00 million. During the same period in the previous year, the business earned $0.76 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 34.3% compared to the same quarter last year. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 3.07 EPS for the current year.

In other news, EVP Stuart A. Arbuckle sold 2,125 shares of the stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $181.89, for a total value of $386,516.25. Following the completion of the sale, the executive vice president now owns 35,365 shares of the company’s stock, valued at approximately $6,432,539.85. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Paul M. Silva sold 161 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $165.41, for a total value of $26,631.01. Following the completion of the sale, the senior vice president now directly owns 17,759 shares of the company’s stock, valued at approximately $2,937,516.19. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 224,305 shares of company stock valued at $39,305,510. Company insiders own 0.70% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Featured Article: How mutual funds make money

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.